Clinical trial
Intermittent Chemotherapy With or Without Granulocyte-macrophage…
NCT00488982 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00488982 |
|---|---|
| Title | Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC) |
| Official title | A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy With Maintenance GM-CSF in Patients With Previously Untreated Hormone Refractory Prostate Cancer |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Docetaxel and GM-CSF |
| Enrollment | 125 |
| Start date | Apr 1, 2007 |
| Primary completion | Mar 1, 2014 |
| Completion | May 1, 2014 |
| First posted | Jun 20, 2007 |
| Last update posted | Nov 20, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: